Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.

Current hematologic malignancy reports - 1 May 2007

Swords Ronan, Alvarado Yesid, Cortes Jorge, Giles Francis J

Abstract excerpt

Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a single genetic abnormality, characterized by a reciprocal translocation involving chromosomes 9 and 22 (the Philadelphia chromosome). The fusion gene that results (BCR-ABL) produces a constitutively activated tyrosine kinase that exists in different isoforms depending on BCR break-points. Imatinib mesylate is a highly selective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dasatinib
Share to Drug Delivery Systems
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drugs, Investigational

Share to Fusion Proteins, bcr-abl

Share to Genes, abl

Share to Multicenter Studies as Topic

Share to Thiazoles

Source

Identifiers

PMID: 20425355
DOI: 10.1007/s11899-007-0012-4

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.PMID 20425355Read ↗

Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.Semantic proximity Read ↗

New and established tyrosine kinase inhibitors for chronic myeloid leukemiaSemantic proximity Read ↗

State-of-the-art in the treatment of chronic myeloid leukaemia.Semantic proximity Read ↗

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.Semantic proximity Read ↗

Imatinib mesylate for the treatment of chronic myeloid leukemiaSemantic proximity Read ↗

Imatinib Mesylate — The New Gold Standard for Treatment of Chronic Myeloid LeukemiaSemantic proximity Read ↗

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapySemantic proximity Read ↗

Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and managementSemantic proximity Read ↗

Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.Semantic proximity Read ↗

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Semantic proximity Read ↗

Targeted Drugs in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.